key: cord-0991520-9ztagh01 authors: Wang, Fengyuan; Chen, Guopu; Zhao, Yuanjin title: Biomimetic nanoparticles as universal influenza vaccine date: 2020-04-13 journal: Smart materials in medicine DOI: 10.1016/j.smaim.2020.03.001 sha: c947f644fe2bb88d61d3baba16922eb6440ae423 doc_id: 991520 cord_uid: 9ztagh01 Abstract Pandemic virus infections, such as seasonal influenza, severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, pose a major public health threat globally. 1 , 2 Much effort has been devoted to suppress the virus, including vaccine prevention, autoimmunity enhancement, and anti-virus drugs treatment. Among these strategies, development of novel and improved vaccine technologies attracts broad attention as they can nip the virus outbreak in the bud and avoid the appearance of public health emergency. Therefore, Wang et al. 1 recently offer a promising means: they develop universal viral vaccine through biomimetic nanoparticles. The conventional vaccines function by inducing primarily neutralizing antibody responses against viral hemagglutinin and neuraminidase. 3 Whereas, these surface proteins undergo continuous antigenic drift, leading to reduced coverage and limited efficacy of these vaccines, especially against novel pandemic viruses. In contrast to B cells-produced antibody responses, lung CD8 + resident memory T cells (T RM cells) induced after natural viral infection can provide heterosubtypic protection against a variety of virus subtypes. 4 Similarly, replicating vaccines, such as live vector-engineered influenza vaccines, can induce CD8 + T RM cells. However, efficacy of these vaccines is limited because a balance must be maintained between immunogenicity and safety, and they are suitable in only some populations due to compromise with preexisting immunity. Moreover, nonreplicating viral vaccines are alternative strategies, but poor T cell immunity response can be induced by them. Hence, some researchers have turned to materials science for inspiration in overcoming these shortcomings. Many materials have been synthesized and employed for the development of Although promising advance has been made toward universal influenza vaccines through PS-biomimetic nanoparticles combined with inactivated influenza virus to elicit T cell-mediated heterosubtypic immunity, this strategy is still mainly biological vaccine and far away from pure chemical vaccine. For future development, two main aspects are still desired: first, new advances in virology should be made to realize rapid identification of novel virus and analysis of antigen to provide effective templates for real pure chemical vaccines fabrication; second, more materials and chemical synthesis methods, such as nanotechnology, microfluidic technology and microfabrication technology etc., should be developed or employed to bring improved chemical vaccines into reality and simplify the vaccine process. We believe that the multidisciplinary collaboration is promising to realize these challenges and make conceptual and technological advances of modern vaccinology. The hydrophilic cGAMP is prevented from accessing AECs by PS layer, while recognized with PS -biomimetic nanoparticles encapsulation (Panel A). The PS-GAMP concerted with SP-A or SP-D leads to uptake by AMs. Afterwards, cGAMP is released from nanoparticles into the cytosol and transferred to AECs through gap junction. STING protein is activated in these cells, inducing vigorous production of immune mediators, stimulating recruitment of CD11b + DC, and leading to T RM cells and a robust effector CD8 + T cell response. Heterosubtypic protection is thus conferred to against various influenza viruses. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Broadly protective human antibodies that target the active site of influenza virus neuraminidase SnapShot: resident memory T cells Cyclic GMP-AMP signalling protects bacteria against viral infection She is now learning from Prof. Yuanjin Zhao at the Medical School of Nanjing University. Her current scientific interests are focused on biomaterials and microneedles Guopu Chen received his master's degree from the Medical School of Nanjing University in 2019. He is now a Ph.D. student under the supervision of Prof. Jianan Ren and Yuanjin Zhao at the Medical School of Nanjing University. His current scientific interests are focused on hydrogel and their biomedical applications Yuanjin Zhao is a full professor at the Medical School of Nanjing University. He received his Ph.D. degree in 2011 from the School of Biological Science and Medical Engineering of Southeast University The authors declare that they have no conflict of interest.